<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610178</url>
  </required_header>
  <id_info>
    <org_study_id>15-14-30012</org_study_id>
    <nct_id>NCT03610178</nct_id>
  </id_info>
  <brief_title>Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus</brief_title>
  <official_title>Genetic and Epigenetic Mechanisms of Developing Gestational Diabetes Mellitus and Its Effects on the Fetus: a Randomised Controlled Trial of Different Glycemic Targets During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial of different glycemic targets during tratment of women
      with GDM with assessement of epygenetic aspects of their effects on the fetus and pregnancy
      outcomes. This study is interventional, randomised controlled trialr, open-label.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to clarify the effect of hyperglycemia and its correction, the level of
      physical activity and consumption of major macro- and micronutrients by women during
      pregnancy on DNA methylation and expression of genes involved in neuroendocrine regulation
      and development of metabolic diseases in offspring, as well as functional characteristics of
      human umbilical vein endothelial cells (HUVECs). For the purpose of the study women with GDM
      are randomised to 2 treatment groups per glycemic targets ( very tight and tight-moderate
      glycemic targets). Data on glycenmic levels during the study and consumption of major macro-
      and micronutrients will be collected using a mobile application with electronic dairies
      report forms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Women with GDM are randomised to 2 treatment groups: group 1 - treatment group with very tight glycemic targets (&lt;5.1 mmol / L fasting glucose and &lt;7.0 mmol / l hour after a meal) and group 2 - treatment group with tight-moderate glycemic targets (&lt;5.3 mmol / L fasting glucose and &lt;7.8 mmol / l in an hour after a meal).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LGA newborns</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Number (%) of large for gestational age (LGA) newborns</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TRIB1</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Level of expression of TRIB1 gene</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LEP</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Level of expression of LEP gene</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADIPOQ</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Level of expression of ADIPOQ gene</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ANGPTL4</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Level of expression of ANGPTL4 gene</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NR3C1</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Level of expression of NR3C1 gene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cesarian sections</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Number (%) of deliveries by Cesarian sections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGA newborns</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Number (%) of small for gestationa age (SGA) newborns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methylation of candidate genes</measure>
    <time_frame>within 24 hours after delivery</time_frame>
    <description>Levels of methylation (%) of candidate genes with confirmed differences in the expression in HUVECs isolated within 24 hours after delivery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>very tight glycemic targets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tight-moderate glycemic targets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only observation in women with normal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Life-style modification, insulin therapy if needed</intervention_name>
    <description>All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (&lt;5.1 mmol/L fasting and &lt;7.0 mmol/L postprandial) are not achieved insulin therapy is started</description>
    <arm_group_label>tight-moderate glycemic targets</arm_group_label>
    <arm_group_label>very tight glycemic targets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Life-style modification, insulin therapy if needed</intervention_name>
    <description>All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (&lt;5.3 mmol/L fasting and &lt;7.8 mmol/L postprandial) are not achieved insulin therapy is started</description>
    <arm_group_label>tight-moderate glycemic targets</arm_group_label>
    <arm_group_label>very tight glycemic targets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with GDM diagnosed according to the Russian national consensus and the
             recommendations of the International Association of Diabetes and Pregnancy Study
             Groups (fasting glucose of ≥5.1 mmol/L, and/or ≥10.0 mmol/L after 1 h, and/or ≥8.5
             mmol/L after 2 h in oral glucose tolerance test (OGTT) with 75 g of glucose).

          -  Gestational age at the time of inclusion in the study 12 weeks 0 days - 31 weeks 6
             days

          -  For control group: pregnant women with normal glucose tolerance confirmed by OGTT at
             24-31 weeks of gestation.

        Exclusion Criteria:

          -  Diabetes mellitus type 1 and tipe 2

          -  Other deseases that affect methabolism of carbohydrates

          -  Use of drugs that affect methabolism of carbohydrates

          -  Malformations of the fetus identifired prior to inclusion to the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gestation</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Griniva Elena, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Almazov NMRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Polina Popova, MD, PhD</last_name>
    <phone>+78127550595</phone>
    <email>pvpopova@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Almazov NMRC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polina Popova, MD, PhD</last_name>
      <phone>+78127025595</phone>
      <email>pvpopova@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

